Celldex Therapeutics Inc., of Needham, said its Phase 2b study of the experimental treatment CDX-011 — for patients with a certain type of advanced breast cancer — showed an overall survival benefit. Brean Capital called the results impressive, telling clients the drug “targets a clear and large unmet need.” Celldex’s chief medical officer said the company will have talks with the FDA this month on “a pivotal study” designed to pave the way for marketing approval.
Celldex drug trial heartens investors
You have reached the limit of 10 free articles a month
Stay informed with unlimited access to Boston’s trusted news source.
- High-quality journalism from the region’s largest newsroom
- Convenient access across all of your devices
- Today’s Headlines daily newsletter
- Subscriber-only access to exclusive offers, events, contests, eBooks, and more
- Less than $1 a week